Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE

帕妥珠单抗 曲妥珠单抗 医学 紫杉烷 曲妥珠单抗 内科学 肿瘤科 多西紫杉醇 乳腺癌 转移性乳腺癌 耐受性 危险系数 癌症 卡培他滨 紫杉醇 人表皮生长因子受体2 化疗 表皮生长因子受体 不利影响 养生 置信区间
作者
Edith A. Perez,Carlos H. Barrios,W. Eiermann,Masakazu Toi,Young Hyuck Im,Pierfranco Conte,Miguel Martín,Tadeusz Pieńkowski,Xavier Pivot,Howard A. Burris,Jennifer Petersen,Sanne de Haas,Silke Hoersch,Monika Patre,Paul Ellis
出处
期刊:Cancer [Wiley]
卷期号:125 (22): 3974-3984 被引量:61
标识
DOI:10.1002/cncr.32392
摘要

In the phase 3 MARIANNE trial, trastuzumab emtansine (T-DM1) with or without pertuzumab showed noninferior progression-free survival and better tolerability than trastuzumab plus a taxane (HT) for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer. This article reports the final descriptive overall survival (OS) analysis, updated safety data, and additional patient-reported outcomes and biomarker analyses.OS was assessed in 1095 patients with HER2-positive breast cancer and no prior therapy for advanced disease who had been randomized to HT, T-DM1 plus a placebo (hereafter T-DM1), or T-DM1 plus pertuzumab (T-DM1+pertuzumab). A post hoc exploratory landmark analysis of OS, baseline patient and disease characteristics, and tumor biomarkers in patients with and without an objective tumor response (OR) according to the Response Evaluation Criteria in Solid Tumors within 6.5 months of randomization was conducted.The median OS was similar across groups (50.9, 53.7, and 51.8 months for the HT, T-DM1, and T-DM1+pertuzumab groups, respectively). Among patients with an OR, the median OS was longer with T-DM1 (64.4 months) and T-DM1+pertuzumab (not reached) versus HT (56.3 months). No baseline characteristics or biomarkers were strongly associated with OR. The incidence of grade 3 or higher adverse events was greater with HT (55.8%) than T-DM1 (47.1%) or T-DM1+pertuzumab (48.6%). The median time to clinically meaningful deterioration (a 3-point or greater change) in neurotoxicity symptoms was shorter with HT (2.1 months) and T-DM1+pertuzumab (4.2 months) than T-DM1 (6.2 months). Fewer patients reported alopecia and diarrhea and were bothered by treatment side effects in the T-DM1 arm.These results support T-DM1 as a first-line treatment for patients with HER2-positive metastatic breast cancer who are deemed unsuitable for taxane-based therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彪行天下完成签到,获得积分10
5秒前
danli完成签到 ,获得积分10
6秒前
guangyu完成签到,获得积分10
8秒前
学术老6完成签到,获得积分10
9秒前
c123完成签到 ,获得积分10
11秒前
恐怖稽器人完成签到,获得积分10
11秒前
WXR完成签到,获得积分10
12秒前
科研小白完成签到,获得积分10
12秒前
13秒前
可爱丸子完成签到,获得积分10
13秒前
皮汤汤完成签到 ,获得积分10
14秒前
JXDYYZK完成签到,获得积分10
15秒前
SYLH应助lu采纳,获得10
15秒前
Servant2023完成签到,获得积分10
15秒前
鸽子的迷信完成签到,获得积分10
17秒前
nine2652完成签到 ,获得积分10
18秒前
烂漫的睫毛完成签到 ,获得积分10
20秒前
量子星尘发布了新的文献求助10
20秒前
陈老太完成签到 ,获得积分10
21秒前
宇宇宇c完成签到,获得积分10
22秒前
zxt完成签到,获得积分10
23秒前
大橙子发布了新的文献求助10
26秒前
聪明静柏完成签到 ,获得积分10
28秒前
kimiwanano完成签到,获得积分10
30秒前
lu完成签到,获得积分10
31秒前
Profeto应助齐嫒琳采纳,获得10
32秒前
33秒前
情怀应助科研通管家采纳,获得10
34秒前
从来都不会放弃zr完成签到,获得积分10
38秒前
1459完成签到,获得积分10
40秒前
行者+完成签到,获得积分10
40秒前
GongSyi完成签到 ,获得积分10
41秒前
Boris完成签到 ,获得积分10
43秒前
哭泣笑柳完成签到,获得积分10
43秒前
万能图书馆应助大橙子采纳,获得10
46秒前
大眼睛土豆完成签到,获得积分10
50秒前
一条虫gg完成签到,获得积分10
53秒前
54秒前
55秒前
58秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038157
求助须知:如何正确求助?哪些是违规求助? 3575869
关于积分的说明 11373842
捐赠科研通 3305650
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022